Using the EU-OPENSCREEN bioactives library: Identification of Inhibitors of SARS-CoV-2 3CL-Pro Enzymatic Activity Using a Small Molecule in Vitro Repurposing Screen:

Compound repurposing is an important strategy for the identification of effective treatment options against SARS-CoV-2 infection and COVID-19 disease. The EU-OPENSCREEN high capacity screening partner site, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP in Hamburg, Germany, applied high-content screening to a large drug repurposing collection investigating compound’s ability to inhibit SARS-CoV-2 cytopathicity in the human epithelial colorectal adenocarcinoma cell line, Caco-2. By targeting the SARS-CoV-2 main protease 3CL-Pro that plays a central role in viral replication, the study confirmed previously reported inhibitors and identified 62 additional compounds with promising anti-viral activity. 

► Read here the highlight by EU-OPENSCREEN. (